[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiogenic-shock\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiogenic-shock":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,90,0,25,[9,53,76,117,148,183,209,231,253,277,298,337,358,378,405,427,455,485,516,544,562,591,616,636,663],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100492965","phase-1-individualized-or-conventional-transfusion-strategies-during-peripheral-va-ecmo-100492965",false,"NCT05699005","Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO","Comparison of an Individualized Transfusion Strategy to a Conventional Strategy in Patients Undergoing Peripheral Veno-arterial ECMO for Refractory Cardiogenic Shock: a Randomized Controlled Trial - ICONE","ICONE","Inclusion Criteria:\n\n* Age of 18 and older,\n* supported by peripheral VA-ECMO\n* for cardiogenic shock\n* Life expentency \\>90 days\n* Central venous line available ScVO2 measurement\n\nExclusion Criteria:\n\n* Pregnancy,\n* Lack of health insurance,\n* Opposition to blood transfusion,\n* Known congenital hemoglobin disease or disorder,\n* Metabolic alcaloosis with pH\\>7.8,\n* eCPR,\n* Legally incapacitated adults","ALL","18 Years",{"count":21,"type":22},236,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This multicenter randomized controlled trial compare two transfusion strategies of red blood cells transfusion in patients supported by veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock.\n\nAn individualized transfusion strategy based on ScVO2 level, is compared to a conventionnal strategy based on predefined hemoglobin threshold. The primary endpoint is the consumption of packed red blod cells, secondary endpoints are subgroup analysis, mortality, morbidity, and cost-effectiveness",[28,29,30,31,32],"Cardiogenic Shock","Extracorporeal Membrane Oxygenation","Transfusion Related Complication","Anemia","Oxygen Delivery",[34,35,36,37,38,39],"ECMO","ECLS","Refractory cardiogenic shock","Transfusion","ScVO2","Outcome","RECRUITING","2026-06-30",{"date":43,"type":44},"2026-07-02","ACTUAL",{"date":46,"type":44},"2023-09-18",{"date":48,"type":22},"2028-12-18",{"name":50,"class":51},"University Hospital, Lille","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":58,"conditions":64,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100539762","abiomed-impella-rt-daq---observational-study-100539762","NCT06308055","Abiomed Impella RT-DAQ - Observational Study","Abiomed IMPELLA-RT-DAQ - Impella Real Time Data AcQuisition","Inclusion Criteria:\n\n1. Ongoing or planned intensive care management with Impella support\n2. Presence or planned placement of a cardiac output measurement\n\n   1. Preferentially pulmonary catheter (including cardiac output (CO) preferred as continuous measurement)\n   2. Other means of discontinuous CO measurement incl. echocardiography, other thermodilution methods\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Pregnancy\n3. Anticipated support duration \\\u003C24 h",{"count":61,"type":22},125,"2 Days","OBSERVATIONAL",[28],"2026-06-16",{"date":67,"type":44},"2026-06-17",{"date":69,"type":44},"2024-10-04",{"date":71,"type":22},"2027-12-31",{"name":73,"class":74},"Abiomed Inc.","INDUSTRY",4,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":95,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":52},"100641181","compare-vent-feasibility-pilot-study-100641181","NCT07656259","COMPARE-VENT Feasibility Pilot Study","COMPARE-VENT Feasibility Pilot Study: A Pragmatic Cluster Randomized Crossover Trial for Ventilation Strategies and Hemodynamic Impact in Critically Ill Patients With Cardiovascular Disease","Inclusion Criteria:\n\nEligible adults ≥ 18 years of age admitted to the cardiac ICU with need for invasive mechanical ventilation of expected duration \\>12 hours.\n\nPre-Specified Subgroups for exploratory outcomes:\n\n1. SCAI Stages C-E Cardiogenic Shock\n2. Mechanical circulatory support use, including intra-aortic balloon pumps and microaxial flow pumps, including Impella CP, RP Impella Flex, and Impella 5.5 devices\n3. Heart failure with reduced ejection fraction: LVEF \\\u003C40% or;\n4. Moderate to severe RV systolic dysfunction or;\n5. Moderate to severe Pulmonary hypertension, as defined by ACC\u002FAHA\u002FESC guidelines\n\nExclusion Criteria:\n\n1. Expected duration of intubation \\\u003C12 hours.\n2. Severe COPD, bronchopleural fistulas, or severe ARDS (Berlin criteria P\u002FF \\\u003C100, in the absence of pulmonary edema)\n3. Home ventilator or chronic tracheostomy.\n4. Pregnant, incarcerated, patients or those receiving extracorporeal membrane oxygenation",{"count":84,"type":22},75,[86],"NA","Cardiac disease complicated by respiratory insufficiency comprises the most frequent indication for cardiac intensive care unit (CICU) admission, with nearly one-third patients requiring advanced respiratory support and over 20% patients requiring invasive mechanical ventilation (IMV). IMV among patients with impaired cardiovascular reserve is further compounded by the adverse impact of positive pressure ventilation (PPV) and systemic sedation on intracardiac hemodynamics, pulmonary vascular mechanics and consequently end-organ perfusion. Despite widespread use, evidence guiding optimal ventilatory practices and mode selection in cardiovascular intensive care unit patients remains limited. Pressure-controlled and volume-controlled ventilation may differ in their effects on patient-ventilator synchrony, sedation requirements, and hemodynamic impact, but comparative data among patients with critical cardiac disease remains inconclusive. This pilot study will evaluate the feasibility of implementing a pragmatic cluster-randomized crossover trial comparing ventilatory modes in a contemporary cardiovascular intensive care unit.",[89,90,91,92,93,28,94],"Respiration Failure","Cardio Vascular Disease","Cardiogenic Pulmonary Oedema","Critical Illness","Mechanical Ventilation","Cardiopulmonary",[96,97,98,99,100,101,102,103,104,105,106],"Cardiovascular disease","Cardiac arrest","Cardiogenic shock","Respiratory failure","Cardiopulmonary interactions","Critical illness","Intensive care unit","Critical care therapies","Outcomes","Mechanical ventilation","Positive pressure ventilation","NOT_YET_RECRUITING","2026-06-14",{"date":110,"type":44},"2026-06-18",{"date":112,"type":22},"2026-07-01",{"date":114,"type":22},"2027-06-30",{"name":116,"class":51},"Mayo Clinic",{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":52},"100642943","cardiovascular-outcomes-registry-in-cardiogenic-shock-cor-shock-100642943","NCT07597291","Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK)","Cardiovascular Outcomes Registry in Cardiogenic SHOCK","COR-SHOCK","Inclusion Criteria:\n\n-Cardiogenic shock according to the following criteria:\n\nCardiac disorder resulting in hypotension, defined as at least one of the following:\n\n* Systolic blood pressure (SBP) \\\u003C90 mmHg for ≥30 minutes, or\n* Requirement for vasopressors, inotropes, or mechanical circulatory support to maintain SBP ≥90 mmHg\n\nAND\n\nEvidence of tissue hypoperfusion, defined by the presence of at least one of the following:\n\n* Serum lactate \\>2 mmol\u002FL\n* Acute kidney injury and\u002For oliguria\n* Acute hepatic injury\n* Cool or mottled extremities\n* Altered mental status\n\nAND\n\nClinical presentation judged to be primarily attributable to a cardiac etiology.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Other primary etiologies of shock at presentation (e.g., hypovolemic, hemorrhagic, septic, obstructive shock due to acute pulmonary embolism, or anaphylactic shock).\n* Refusal to participate in the study (applicable only to the prospective cohort).",{"count":126,"type":22},800,"The goal of this observational study is to evaluate the clinical outcomes and management approaches of cardiogenic shock throughout the years in adult patients admitted to a Cardiology Department. The main questions it aims to answer are:\n\n* How have management strategies and clinical outcomes for cardiogenic shock evolved over time?\n* How do clinical, laboratory, and advanced hemodynamic monitoring parameters relate to patient survival and overall prognosis in this population?\n\nResearchers will evaluate clinical data collected from 2017 onwards to see if therapeutic advancements and changes in clinical management over the years have led to improved patient survival and quality of care.\n\nParticipants will:\n\n* Receive standard, routine medical care for cardiogenic shock as determined by their clinical team (no experimental interventions will be introduced).\n* Have their clinical, laboratory, and imaging data collected from hospital electronic records during their stay.\n* Be followed for up to 1 year after hospital admission to evaluate long-term survival and clinical outcomes.",[129,28,130],"Cardiogenic Shock Acute","Cardiogenic Shock Post Myocardial Infarction",[28,132,133,134,135,136,137,138],"Shock, Cardiogenic","Hemodynamic Monitoring","Pulmonary Artery Catheterization","Swan-Ganz","Mechanical Circulatory Support","Prognosis","Myocardial Infarction","2026-06-09",{"date":141,"type":44},"2026-06-11",{"date":143,"type":44},"2026-06-10",{"date":145,"type":22},"2036-12-31",{"name":147,"class":51},"Hospital de Santa Cruz, Portugal",{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":156,"targetDuration":158,"studyType":63,"phases":4,"briefSummary":159,"conditions":160,"keywords":167,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":52},"100643069","beat-shock-registry-100643069","NCT07643610","BEAT-SHOCK Registry","BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry","BEAT-SHOCK","* Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay\n* Age ≥18 years\n* Provision of written ICF\n* Clinical diagnosis of cardiogenic shock.\n* impaired organ perfusion due to primary cardiac dysfunction,\n* persistent systolic blood pressure (SBP) \\\u003C90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and\n* evidence of systemic hypoperfusion with arterial lactate ≥2 mmol\u002FL or venous lactate ≥3 mmol\u002Fl and ≥1 of the following:\n* Cold or clammy extremities\n* Altered mental status\n* Reduced urine output\n* Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring)\n* Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol\u002FL or venous lactate ≥3 mmol\u002Fl) and cardiac dysfunction are present and alternative causes are excluded\n\nExclusion criteria:\n\n* Age \\\u003C18 years\n* Refusal to provide informed consent by the patient or their legally authorized representative",{"count":157,"type":22},8000,"5 Years","This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.",[28,161,162,163,164,165,166],"Myocardial Infarction (MI)","Fulminant Myocarditis","Acute Decompensated Heart Failure","Severe Valvular Disease","Post-cardiotomy","Perioperative Cardiogenic Shock",[168,169,170,171,172,173,174],"cardiogenic shock","Myocardial infarction (MI)","Fulminant myocarditis","Acute decompensated heart failure","Severe valvular disease","Post-cardiotomy or perioperative cardiogenic shock","wide range of cardiogenic shock etiologies","2026-06-08",{"date":141,"type":44},{"date":178,"type":44},"2025-10-01",{"date":180,"type":22},"2035-10-01",{"name":182,"class":51},"University Hospital, Basel, Switzerland",{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":52},"100638835","optimize-55---optimizing-impella-55-outcomes-through-advanced-data-science-100638835","NCT07619144","OPTIMIZE 5.5 - Optimizing Impella 5.5 Outcomes Through Advanced Data Science","Clinical Outcomes and Adverse Events Associated With Microaxial Flow Pump Support: An Explorative Retrospective Study","OPTIMIZE","Inclusion Criteria:\n\n* Adult patients who were treated for cardiogenic shock and supported with an Impella 5.5 micro-axial flow pump\n* Only patients with available high-resolution pump data (downloaded from the clinical console) and ICU digital health record datasets\n\nExclusion Criteria:\n\n* Patients supported with an Impella 5.5 for indications other than cardiogenic shock (e.g., protected PCI or CABG)\n* Patients younger than 18 years\n* Patients with incomplete data, procedural records, or demographic information",{"count":192,"type":22},100,"The main goal of this observational, study is to develop a clinical decision support tool utilizing Impella 5.5 pump parameters to predict native heart recovery and prevent adverse events, by leveraging data science and real-world clinical data of cardiogenic shock patients.\n\nTherefore, secondary objectives are essential to consolidating a retrospective longitudinal analysis of Impella 5.5 pump data alongside ICU digital health record datasets to:\n\n1. Validate the Impella 5.5 placement signal by comparing it with ICU arterial line waveforms.\n2. Integrate pump data with ICU clinical data to identify patterns associated with therapy outcomes, including native heart recovery, heart replacement therapy, and mortality while on device support.\n3. Define clinical scenarios linked to hemolysis, HRAEs, and arrhythmias and develop predictive models to mitigate their occurrence.",[28,136,130],[168,196,197,198,199],"mechanical circulatory support","Impella 5.5","micro-axial flow pump","data science","2026-05-27",{"date":202,"type":44},"2026-06-01",{"date":204,"type":44},"2026-05-08",{"date":206,"type":22},"2029-05-30",{"name":208,"class":51},"Medical University of Vienna",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":4},"100638205","oxygen-delivery-index-odin-study-100638205","NCT07601828","Oxygen Delivery Index (ODIN) Study","A Single-Site, Pilot Study Using ODI Technology to Measure Microvascular Function and Oxygen Extraction in Patients With Advanced Heart Failure and Cardiogenic Shock","Inclusion Criteria:\n\n* 18 years or older\n* Diagnosed with advanced heart failure or cardiogenic shock\n* Patient already has a pulmonary artery catheter placed\n\nExclusion Criteria:\n\n* Inability to obtain consent from the patient (including patients who are intubated at time of consent)\n* Liver or kidney transplant patients\n* Patients on dialysis\n* Patients with ongoing chronic alcohol use disorder or substance abuse disorder\n* Patients on home assisted mechanical ventilation (via tracheotomy or noninvasive) or requiring home oxygen.\n* Patients with a recent cardiac arrest\n* Patients with severe neurologic injury or dysfunction.\n* Prisoners\n* Patients with decisional impairment\u002F cognitive decline.",{"count":217,"type":22},30,[86],"The objective of this study is to test the feasibility and efficacy of a novel, non-invasive electronic device to monitor the adequacy of tissue perfusion in patients with advanced heart failure or cardiogenic shock in the ICU.\n\nThis single-site pilot study will evaluate the FDA-approved Oxygen Delivery Index (ODIN), a non-invasive method for assessing microvascular function and oxygen extraction, in patients with advanced heart failure and cardiogenic shock. ODIN comprises ODI Technology (including CAM, DRS, a medical PC, and an enclosure), a standardized data acquisition procedure, and proprietary analysis software.\n\nThirty consecutive patients will be enrolled upon hospital presentation, undergoing ODIN measurement alongside standard clinical assessments.\n\nODI Tech data are collected solely for research correlation with established diagnostic standards; measurements will not be used to diagnose or contribute to any clinical decision making, and will not be used for any clinical indication or guidance.",[221,28],"Heart Failure","2026-05-18",{"date":224,"type":44},"2026-05-22",{"date":226,"type":22},"2026-05",{"date":228,"type":22},"2028-05",{"name":230,"class":51},"NYU Langone Health",{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":238,"targetDuration":240,"studyType":63,"phases":4,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":52},"100385172","altshock-2-registry-100385172","NCT04295252","Altshock-2 REGISTRY","Cardiogenic Shock: a Prospective National Registry to Get Insights in Patients' Profile, Management and Outcome","All consecutive CS patients hospitalized in the above reported centres between January 2020 and December 2030.\n\nCardiogenic shock is defined as:\n\n1. Systolic blood pressure (SBP) \\\u003C90 mmHg or mean arterial pressure (MAP) \\\u003C60 mmHg, after an appropriate fluid challenge if there is no sign of overt fluid overload, OR need of vasoactive agents to maintain SBP \\> 90 mmHg or MAP \\> 60 mmHg, OR need of MCS;\n2. At least one of the following criteria\u002Fsigns of overt hypoperfusion: mixed venous oxygen saturation \\\u003C60%; arterial lactates \\> 2 mmol\u002FL; oliguria \\\u003C 0.5 ml\u002FKg\u002Fh for at least 6 hours.",{"count":239,"type":22},3000,"1 Day","The study will provide data on profile, management, outcome, and evolution over time of cardiogenic shock patients admitted to the Intensive Coronary Care Units",[28],[168],"2026-05-13",{"date":246,"type":44},"2026-05-14",{"date":248,"type":44},"2020-07-01",{"date":250,"type":22},"2031-12-31",{"name":252,"class":51},"Niguarda Hospital",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":23,"phases":264,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":4},"100638928","phase-2-randomized-evaluation-of-istaroxime-for-stabilization-in-acute-heart-failure-cardiogenic-shock-100638928","NCT07583446","Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock","A Randomized, Double-blind, Phase 2b\u002F3 Clinical Study of Istaroxime Combined With Standard Care Versus Placebo and Standard of Care for the Treatment of Cardiogenic Shock (CS) Society for Cardiovascular Angiography and Interventions (SCAI) Stage B or C Due to Acute Heart Failure (AHF)","RESCUE HF-CS","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old (inclusive) at the time of informed consent, regardless of gender.\n2. Diagnosed with CS SCAI B or C due to AHF during screening, before randomization, as defined by:\n\n   1. Dyspnea at rest or with minimal activity before screening and randomization.\n   2. Pulmonary rales, or lower limb edema by physical examination.\n   3. Evidence of pulmonary congestion by chest X-ray, CT scan or lung ultrasound\n   4. At the time of screening and just prior to randomization either:\n\n      1. systolic BP ≤ 100 mmHg or\n      2. systolic BP ≤ 115 mmHg and \\>100 mmHg accompanied by at least one sign of hypoperfusion or hemodynamic compromise: cool extremities, altered mentation attributable to low output, oliguria, elevated lactate (\\>2 mmol\u002FL), worsening renal function attributable to low perfusion, or invasive\u002Fnoninvasive hemodynamic evidence of reduced cardiac output.\n3. Admitted for AHF within 20 hours before randomization.\n4. Documented history within 6 months prior to screening, or during the current admission, of left ventricular ejection fraction (LVEF) \\\u003C 40%.\n5. New York Heart Association (NYHA) functional class ≥ II at 1 month prior to admission.\n6. N-terminal pro-B-type natriuretic peptide (NT-proBNP) \\> 1,500 pg\u002FmL or BNP \\> 400 pg\u002FmL during screening, before randomization.\n7. Signed informed consent as described in Section 11.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\n1. Body weight \\\u003C 40 kg or ≥ 150 kg at Screening.\n2. Society for Cardiovascular Angiography and Interventions (SCAI) level D or more severe cardiogenic shock during screening, prior to randomization.\n3. Patients with any systolic blood pressure measurement \\>130 mmHg within 2 hours prior to randomization.\n4. Administration during the 6 hours prior to screening of vasodilators such as nitroglycerin, nitrates, recombinant human brain natriuretic peptide\n5. Prescription of digoxin within 7 days before randomization.\n6. Patients with severe lung disease (dependent on oral steroids or immunosuppressive therapy or require home oxygen therapy), respiratory failure, or severe pulmonary hypertension.\n7. Acute ischemic or hemorrhagic cerebral infarction or transient ischemic attack within 30 days before screening.\n8. Abnormal laboratory findings including during screening:\n\n   1. Renal impairment (eGFR \\\u003C 25 ml\u002Fmin\u002F1.73 m2) or the need for long-term or intermittent renal support therapy (hemodialysis, ultrafiltration or peritoneal dialysis);\n   2. Severe electrolyte imbalance (Na+ \\\u003C120mmol\u002FL or \\>160mmol\u002FL, and\u002For K+ \\\u003C3.2mmol\u002FL or \\>5.5mmol\u002FL);\n   3. Liver function impairment (ALT and\u002For AST \\> 3 times the upper limit of the normal range and\u002For bilirubin exceeds 1.5 times the upper limit of the normal range);\n   4. Hemoglobin \\\u003C9 g\u002FdL (\\\u003C5.6 mmol\u002FL).\n9. Severe valvular stenosis that has not been surgically corrected, or moderate or severe aortic or pulmonary regurgitation.\n10. Obstructive hypertrophic cardiomyopathy or restrictive cardiomyopathy, constrictive pericarditis, cardiac tamponade, cardiomyopathy based on infiltrative disease (such as amyloidosis), accumulation disease (such as hemochromatosis, Fabry disease), myocardial dysplasia, cardiomyopathy caused by reversible causes (such as stress cardiomyopathy) or acute myocarditis.\n11. Sustained ventricular tachycardia or ventricular fibrillation within 30 days of screening and randomization.\n12. Significant bradycardia (sustained ventricular rate \\\u003C50 beats per minute), or second or third-degree atrioventricular block (except those using permanent pacemakers).\n13. Type 1 acute coronary syndrome (ACS)\u002Fmyocardial infarction (MI) in the 30 days prior to screening inclusive of the current admission.\n14. Patients who have undergone percutaneous coronary angiography or coronary artery bypass grafting or other major cardiovascular surgery including ICD and \u002F or CRT or mechanical support devices within one month before screening, or patients who are expected to require revascularization within three months after screening.\n15. Patients on mechanical circulatory support (MCS) during Screening or at the time of randomization.\n16. Patients who are expected to require heart transplantation or left ventricular assist during the study period.\n17. Patients diagnosed with malignant tumors within 1 year before signing the informed consent form or at the time of screening (excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery), or those undergoing anti-tumor treatment at the time of screening.\n18. Patients with diseases that in the opinion of the investigator may lead to mortality within 90 days from randomization.\n19. Patients who suffer from severe mental or psychological disorders, cognitive impairment, or a history of mental illness.\n20. Patients with known severe allergies or a history of severe drug or food allergic reactions, or those known to be allergic to Istaroxime or its ingredients including lactose.\n21. Patients who are pregnant, breastfeeding or planning pregnancy.\n22. Patients who cannot be guaranteed to take effective contraceptive measures from the time of signing the informed consent to the 30 days following their last exposure to study drug, or who are of childbearing potential and plan to donate sperm\u002Feggs during this period.\n23. Patients of childbearing potential without a negative highly sensitive serum pregnancy test within 24 hours before the first dose of trial intervention.\n24. Patients participating in other clinical studies and\u002For received other study intervention (study drugs or medical devices, etc.) within 30 days before signing the informed consent form, or who are still in the follow up period of other clinical studies.\n25. Patients who are unable to comply with all study requirements.","80 Years",{"count":263,"type":22},600,[265,266],"PHASE2","PHASE3","The goal of this clinical trial is to learn if the drug istaroxime works to treat mild to moderate cardiogenic shock due to acute heart failure in adults. It will also learn about the safety of istaroxime. The main questions it aims to answer are:\n\n* Does istaroxime relieve participants' shortness of breath compared to a placebo?\n* Does istaroxime provide clinical benefit in terms of lowering the risk of dying, having invasive procedures, having worsening heart failure, and\u002For increasing quality of life compared to a placebo?\n* Does istaroxime increase blood pressure compared to a placebo? Researchers will compare istaroxime to a placebo (a look-alike substance that contains no drug) to see if istaroxime works to treat mild to moderate cardiogenic shock due to acute heart failure.\n\nParticipants will:\n\n* Receive a 48-hour intravenous infusion of istaroxime or placebo\n* Complete questionnaires rating their breathing and describing their quality of life\n* Return for a visit 30 and 90 days after the initial drug infusion was started",[28],"2026-05-07",{"date":244,"type":44},{"date":272,"type":22},"2026-07",{"date":274,"type":22},"2028-12",{"name":276,"class":74},"Seismic Pharmaceuticals Operations LLC",{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":261,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":294,"leadSponsor":296,"locationsCount":52},"100636007","catheter-oriented-unloading-and-recovery-with-a-left-ventricular-assist-gear-efficacy-in-post-cardiotomy-cardiogenic-shock-100636007","NCT07560085","Catheter-Oriented Unloading and Recovery With a Left Ventricular Assist Gear: Efficacy in Post Cardiotomy Cardiogenic Shock","Efficacy and Safety of SynFlow Duro System in the Treatment of Post Cardiotomy Cardiogenic Shock: a Prospective, Multicenter, Single-arm Clinical Trial","COURAGE","Inclusion Criteria:\n\n* 18≤Age≤80, any sex.\n* Failure to wean from CPB or refractory cardiogenic shock after cardiac surgery.\n\nFailure to wean from CPB is defined as failed to discontinue CPB or post-weaning CI \\\u003C2.2L\u002Fmin\u002Fm2 + PCWP \\>15mmHg, despite optimal pre-weaning management and receiving at least one high dose inotrope.\n\nRefractory cardiogenic shock is defined as a condition that occurs despite adequate fluid status and meets all the following criteria:\n\n① CI\\\u003C2.2L\u002Fmin\u002Fm2 + PCWP\\>15mmHg despite receiving at least one high dose inotrope or IABP; OR SBP \\\u003C80mmHg or MAP\\\u003C50mmHg despite receiving at least one high dose intrope + high dose norepinephrine or IABP.\n\n② Presence of at least one signs indicating hypoperfusion: decreased mentation; cold, clammy, ashen or cyanotic extremities or skin or livedo reticularis; urine output\\\u003C30ml\u002Fh or 0.5ml\u002Fkg\u002Fh; or lactate\\>2mmol\u002FL or metabolic acidosis.\n\n\\- Patient has signed the informed consent form.\n\nExclusion Criteria:\n\n* Body surface area\\>2.5m2.\n* Presence of any cardiac assist device (other than an IABP).\n* Right ventricular failure.\n* Evidence of any vascular disease or anatomy precluding placement or deployment of the device (e.g. severely calcified vessel).\n* Evidence of ventricular thrombus.\n* Moderate or severe aortic valve insufficiency\u002Fstenosis, or severe aortic valve calcification.\n* Presence of mechanical aortic valve or cardiac contractile device.\n* Obstructive, hypertrophic cardiomyopathy.\n* Presence of uncorrected ventricular septal defect, atrial septal defect or patent foramen ovale.\n* Mechanical manifestation of AMI (e.g. ventricular septal rupture, papillary muscle rupture, ventricular rupture).\n* Any hematological disorder causing fragility of blood vessel or hemolysis.\n* Known allergy or intolerant to heparin.\n* Presence or suspicion of active systemic infection.\n* Cardiopulmonary resuscitative maneuver lasting longer than 20 minutes before device placement.\n* Sustained or non-sustained ventricular tachycardia or ventricular fibrillation unresponsive to medical therapy.\n* Severe hepatic dysfunction, renal failure or severe respiratory failure\n* Pregnant or lactating female.\n* Concomitant enrollment in another investigational drug or device study where the primary endpoint has not yet been completed or that will clinically interfere with the endpoint of this investigation.\n* Other conditions considered unsuitable for participating in this investigation by the investigators.",{"count":286,"type":22},60,[86],"This study is a prospective, multicenter, single-arm clinical trial conducted in China to evaluate the efficacy and safety of a novel left ventricular assist device, SynFlow Duro system, manufactured by ForQaly Medical in the treatment of post cardiotomy cardiogenic shock.",[28],"2026-05-06",{"date":292,"type":44},"2026-05-11",{"date":226,"type":22},{"date":295,"type":22},"2027-06",{"name":297,"class":74},"ForQaly Medical (Shanghai) Co., Ltd",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":316,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":52},"100640195","feasibility-of-protocolised-analgosedation-in-ecmo-100640195","NCT07580781","Feasibility of Protocolised Analgosedation in ECMO","Feasibility of a Cluster Randomised Control Trial Evaluating a Co-designed Analgosedation Protocol in Extracorporeal Membrane Oxygenation (ECMO) Patients","ECMO-SED","Inclusion Criteria:\n\n* Aged 18 years and older\n* Receiving IV continuous infusions of analgosedation medication\n* Receiving ECMO treatment\n\nExclusion Criteria:\n\n* There will be no exclusion criteria as analgosedation management is routine for all adult ECMO patients.",{"count":286,"type":22},[86],"Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable. ECMO is a life support machine that provides oxygen and removes waste gases (carbon dioxide) in very sick patients with severe heart or lung failure. About 300-400 patients per year receive ECMO in the UK. These patients are younger and generally more healthy compared to other critically ill patients. However patients that survive ECMO have long-term health problems. These include anxiety, memory problems, withdrawal from medicines, and mobility issues. These problems issues could all be related to the type and amount of sedation given.\n\nA sedation protocol is a way of guiding healthcare professionals how much sedation is given to patients in ICU. Too much sedation can cause confusion, hallucinations, excessive sleepiness, and longer time in hospital. Too little sedation can cause pain, distress, and also a longer time in hospital. Using a sedation protocol in non-ECMO patients has been shown to reduce these complications.\n\nHowever, there are no protocols for giving sedation to ECMO patients in research papers. Investigators know healthcare staff find it difficult to manage sedation, and higher amounts of sedation is given to ECMO patients.\n\nAims:\n\nTo see whether it is possible to run a trial that compares using a sedation protocol against usual care.\n\nDesign\u002Fmethods:\n\nThirty to 60 ECMO patients will be chosen and will be put into one of two groups. One group will receive usual care, and the other will receive care using the sedation protocol. The investigators will collect information from both groups to find out if the study design works and how many patients agree to take part.\n\nPatient and public involvement\u002Fengagement:\n\nThe investigators received feedback from patients and family member participants which helped to design this proposal, the lay summary and what to measure in a trial. They will advise how the investigators should review study findings, and support sharing of results to the public.\n\nImpact\u002Fdissemination:\n\nThe investigators will share findings through social media, patient charities, research papers and conferences.",[310,311,312,29,313,28,314,315],"Intensive Care (ICU)","Respiratory Distress Syndrome (RDS)","Sedation and Analgesia","Sedation for Mechanical Ventilation","Opioid Analgesia","Analgesia",[317,318,319,320,321,322,34,323,324,325,326,327],"extracorporeal membrane oxygenation","sedation","opioid","sedative","analgosedation","mechanical ventilation","ICU","Intensive Care Unit","Critical Care","sedation protocol","analgesia","2026-05-05",{"date":330,"type":44},"2026-05-12",{"date":332,"type":22},"2026-09-01",{"date":334,"type":22},"2027-08-31",{"name":336,"class":51},"Guy's and St Thomas' NHS Foundation Trust",{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":304,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":347,"conditions":348,"keywords":351,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":52},"100595479","improving-sedation-practice-in-critically-ill-adult-patients-using-a-co-designed-sedation-protocol-100595479","NCT07032987","Improving Sedation Practice in Critically Ill Adult Patients Using a Co-designed Sedation Protocol","Optimising Analgosedation in Extracorporeal Membrane Oxygenation (ECMO) Using a Co-designed Analgosedation Protocol","Stage 1 (multi-centre observational study):\n\nInclusion Criteria:\n\n1. Aged 18 years and older.\n2. Receiving continuous IV infusions of analgosedation (opioids, benzodiazepines, and\u002For propofol).\n3. Receiving ECMO for moderate to severe respiratory failure (PaO2\u002FFiO2 (P\u002FF) ratio \\\u003C20 kilopascals (kPa)) for ≤ 7 days during the week of recruitment.\n4. Non-ECMO ICU patients (control group): must satisfy inclusion criteria 1 and 2, and have received mechanical ventilation for moderate to severe respiratory failure (P\u002FF ratio \\\u003C 20kPa) for at least 48 hours OR mechanical ventilation for cardiovascular disorder (out of hospital cardiac arrest, following cardiothoracic or transplant surgery or percutaneous coronary intervention or acute heart failure).\n\nExclusion Criteria:\n\n1. Anticipated length of ICU stay in recruiting centre for less than 24 hours.\n2. Withdrawal of life-sustaining treatment in the next 24 hours.\n\nStage 2 (mixed methods study):\n\nInclusion Criteria:\n\n1. Healthcare professionals working at one of two ECMO centres (St Thomas' Hospital and Royal Brompton Hospital (part of Guy's and St Thomas' NHS Foundation Trust).\n2. ECMO survivors (patients admitted to ICU and survived ECMO organ support) who have returned home, and recovered.\n3. Family members of ECMO survivors, whose relative is no longer hospitalised.\n\nExclusion Criteria:\n\n1. ECMO survivors currently receiving treatment in hospital.\n2. ECMO survivors with severe cognitive issues (issues with short-term memory and thinking).\n3. ECMO survivors who cannot communicate in English.\n4. Non-ECMO survivors and family members.","100 Years",{"count":346,"type":22},120,"Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable. ECMO is a life support machine that provides oxygen and removes waste gases (carbon dioxide) in very sick patients with severe heart or lung failure. About 300-400 patients per year receive ECMO in the UK. These patients are younger and generally more healthy compared to other critically ill patients. However patients that survive ECMO have long-term health problems. These include anxiety, memory problems, withdrawal from medicines, and mobility issues. These problems issues could all be related to the type and amount of sedation given.\n\nA sedation protocol is a way of guiding healthcare professionals how much sedation is given to patients in ICU. Too much sedation can cause confusion, hallucinations, excessive sleepiness, and longer time in hospital. Too little sedation can cause pain, distress, and also a longer time in hospital. Using a sedation protocol in non-ECMO patients has been shown to reduce these complications.\n\nHowever, there are no protocols for giving sedation to ECMO patients in research papers. The investigators know healthcare staff find it difficult to manage sedation, and higher amounts of sedation is given to ECMO patients.\n\nAims:\n\n* To describe current sedation use in ECMO patients in the UK and compare to non-ECMO critically ill patients.\n* To develop a sedation protocol for ECMO patients with input from patients, their family, and staff.\n\nDesign\u002Fmethods:\n\nStudy 1:\n\nThe investigators will study how sedation is used in adult ECMO patients and compare with non-ECMO but critically ill patients in the UK. The investigators will collect information on drug doses and pain and sedation scores. The investigators will also ask ECMO centres if they use a sedation protocol to adjust sedation doses. This information will be helpful for the design of the protocol in study 2.\n\nStudy 2:\n\nThe investigators will design a sedation protocol with input from patients, family, and staff. The investigators will organise meetings to share experiences and agree on what to include in the protocol that is considered acceptable and safe. The investigators will then assess if the protocol is safe and acceptable with staff outside the co-design group.\n\nPatient and public involvement\u002Fengagement:\n\nThe investigators received feedback from patients and family members which helped to design this proposal, the lay summary and what to measure in a trial. Patients and family members will continue to help with development of the sedation and trial protocol. They will advise how the investigators should review study findings, and support sharing of results to the public.\n\nImpact\u002Fdissemination:\n\nThe investigators will share findings through social media, patient charities, research papers and conferences.",[349,311,312,350,313,28,314,315],"Intensive Care Medicine","ExtraCorporeal Membrane Oxygenation (ECMO)",[317,318,319,352,321,322,34,323,324,325,326,327],"sedatives",{"date":204,"type":44},{"date":355,"type":44},"2025-11-24",{"date":334,"type":22},{"name":336,"class":51},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":376,"locationsCount":75},"100462166","transcatheter-mitral-valve-repair-for-inotrope-dependent-cardiogenic-shock-100462166","NCT05298124","Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock","MINOS","Inclusion Criteria:\n\n1. Participants or substitute decision maker is able and willing to provide written informed consent\n2. Age ≥ 18 years\n3. SCAI stage C or D cardiogenic shock with persistent inotrope\u002Fvasopressor\u002Fnon-durable mechanical support or unable to wean ventilatory support due to pulmonary edema for 24 hours prior to randomization\n4. Greater than or equal to 3+ MR as determined by a study center's transesophageal echocardiogram (TEE)\n5. In the opinion of the study center's heart team the participant is anatomically eligible for TMVr with the potential to achieve \\\u003C3+ MR\n\nExclusion Criteria:\n\n1. Unwilling or unable to obtain informed consent from the participant or substitute decision maker\n2. Revascularization of coronary artery disease performed in the 48 hours prior to randomization\n3. If the mechanism of MR is deemed to be degenerative, in the opinion of the heart team the participant is eligible for surgical intervention\n4. Prior mitral valve leaflet surgery or implanted mitral valve prosthesis (excluding ring)\n5. Echocardiographic evidence of left sided intracardiac mass or thrombus\n6. Diagnosis of active infective endocarditis\n7. Transesophageal echocardiogram is contraindicated\n8. Mitral valve anatomy deemed contraindication to TMVr implantation that cannot be addressed procedurally as determined by the study center's heart team\n9. Any aortic valve disease greater than moderate in severity\n10. A known hypersensitivity or contraindication to procedure medications which cannot be adequately managed medically\n11. Out of hospital cardiac arrest or in-hospital cardiac arrest without documented neurologic recovery\n12. Plan for durable mechanical circulatory support implantation prior to TMVr\n13. In the opinion of the treating team, there is a significant comorbidity that would limit life expectancy in hospital\n14. Pregnant or planning to become pregnant in the next 6 months.",{"count":366,"type":22},144,[86],"Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock.\n\nThis study will be a multicenter, open-label, randomized-controlled trial with two study arms: medical therapy and TEER. Patients admitted to the Cardiac Intensive Care Unit (CICU), Cardiac Surgery Intensive Care Unit (CSICU) or Intensive Care Units (ICU) at participating centers will be recruited.\n\nThe study aims to answer the question: \"Does TEER in patients with SCAI stage C or D cardiogenic with concomitant moderate or greater mitral regurgitation improve outcomes as compared to medical therapy?\"\n\nThe study hypothesis is that TEER will lead to an overall improvement in the composite outcome as compared to the medical therapy arm.",[28,370],"Mitral Regurgitation","2026-04-29",{"date":290,"type":44},{"date":374,"type":44},"2022-05-26",{"date":228,"type":22},{"name":377,"class":51},"Ottawa Heart Institute Research Corporation",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":385,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":391,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":52},"100636226","assessing-catecholamine-treatment-initiation-options-norepinephrine-vs-dopamine-for-cardiogenic-shock-100636226","NCT07562932","Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock","ACTION-CS","Inclusion Criteria: 1\\&2\n\n1. Age ≥ 19\n2. Cardiogenic shocka in the stage of Society for cardiovascular angiography and intervention (SCAI) C or D\n\n   * Cardiogenic shock was defined as follows, and should fulfill both 1) and 2)\n\n     1. systolic blood pressure \\\u003C90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure \\>90 mm Hg And\n     2. Impaired cardiac function confirmed by cardiac catheterization or echocardiography\n   * Patients will be further classified based on the SCAI shock classification system as follows:\n\n     1. SCAI B: no signs of hypoperfusion\n     2. SCAI C: any signs of hypoperfusion, cardiogenic shock will be classified as SCAI C, and these include mental status change, cool and clammy skin, mottled skin appearance, decreased urine output (30ml\u002Fhour) or lactate over 2.0mmol\u002FL\n     3. SCAI D: requirement of second-line vasoactive drug or mechanical circulatory support based on the predefined treatment protocol\n\nExclusion Criteria: any of these,\n\n1. Administration of vasoactive drug more than 6 hours before enrollment\n2. Patients already on temporary mechanical circulatory supportb before enrollment\n3. Glasgow Coma Scale lower than 8 or other evidence of irreversible brain injury\n4. Shock etiologies other than cardiogenic which include postcardiotomy shock or mixed shock\n5. Pregnancy or lactation","19 Years",{"count":387,"type":22},512,[86],"The goal of this multicenter, open-label, randomized clinical trial is to learn whether norepinephrine or dopamine is more effective and safer as the first-line vasoactive drug for treating cardiogenic shock in adults. Cardiogenic shock is a life-threatening condition in which the heart cannot pump enough blood to supply the body. The main questions this study aims to answer are:\n\nDoes norepinephrine reduce the risk of death or worsening cardiogenic shock compared with dopamine?\n\nDoes norepinephrine lead to fewer complications such as arrhythmias, the need for mechanical circulatory support, or cardiac arrest?\n\nResearchers will compare norepinephrine and dopamine to see which drug better stabilizes blood pressure, improves tissue perfusion, and prevents progression of shock during the early phase of treatment.\n\nParticipants will:\n\nBe randomly assigned to receive either norepinephrine or dopamine as the first vasoactive drug\n\nReceive treatment and monitoring based on current clinical guidelines for cardiogenic shock\n\nUndergo regular assessments of blood pressure, laboratory values, heart rhythm, and organ function during hospitalization\n\nBe followed for outcomes at 1 month, 6 months, and 1 year after enrollment\n\nThis study aims to provide evidence that will help determine which initial vasoactive drug offers better outcomes for patients with cardiogenic shock and guide future treatment recommendations.",[28],[392,393,394,395,98],"Vasoactive drug","Norepinephrine","Dopamine","Randomized controlled trial","2026-04-28",{"date":398,"type":44},"2026-05-01",{"date":400,"type":22},"2026-05-31",{"date":402,"type":22},"2032-05-31",{"name":404,"class":51},"Chonnam National University Hospital",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":413,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":52},"100541960","phase-2-physiology-of-unloading-va-ecmo-trial-100541960","NCT06336655","Physiology of Unloading VA ECMO Trial","Inclusion Criteria:\n\n* Adult patients (age 18 years or older)\n* Diagnosis of acute cardiogenic shock (CS)\n* Patients failing medical therapy, defined as 1 or more of the following:\n\n  1. Society for Coronary Angiography and Interventions (SCAI) Stage C or greater\n  2. 2 or more inotropic medications and not improving\n  3. IABP in place and clinically worsening\n  4. Placed on VA ECMO for CS\n  5. In the opinion of the attending physician, patient has worsening CS and could require VA ECMO support in the near-term\n\nExclusion Criteria:\n\n* Metastatic or stage 4 cancer\n* Atrial septostomy\n* Planned LV unloading on ECMO\n* Anticipated death \\\u003C72 hours\n* Existing durable left ventricular assist device (dLVAD)\n* Unwillingness to randomize\n* Patients who are pregnant",{"count":412,"type":22},104,[265],"The goal of this clinical trial is to compare the use of veno-arterial extracorporeal membrane oxygenation (VA ECMO) with and without left ventricular (LV) unloading in patients being treated for cardiogenic shock (CS). The main aims of the study are:\n\n1. To determine the physiologic effects on cardiopulmonary congestion of adding LV unloading to VA ECMO\n2. To determine the effects on myocardial function of adding LV unloading to ECMO\n3. To test the effects on myocardial recovery of adding LV unloading to VA ECMO\n\nParticipants who are being treated with VA ECMO will be randomized to receive or not receive LV unloading in the form of an intra-aortic balloon pump (IABP). Over the course of the study, the investigators will obtain measurements via lab work, echocardiography, and pulmonary artery catheter that will allow comparison of the two groups.",[28],[168,317,417],"left ventricular unloading","2026-04-27",{"date":420,"type":44},"2026-04-30",{"date":422,"type":44},"2024-10-02",{"date":424,"type":22},"2029-02-01",{"name":426,"class":51},"University of Utah",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":261,"enrollmentInfo":435,"targetDuration":4,"studyType":23,"phases":437,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":454},"100590291","initiation-and-titration-of-guideline-directed-medical-therapy-in-heart-failure-cardiogenic-shock-with-impella-55-for-cardiac-recovery-100590291","NCT06965504","INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery","Initiation and Titration of Guideline Directed Medical Therapy in Heart Failure Cardiogenic Shock With Impella 5.5 for Cardiac Recovery: INTeGRATE","INTeGRATE","Inclusion Criteria:\n\n1. Age ≥ 18 and \\\u003C 80 years\n2. Subject has signed the Informed Consent Form. If the subject has been enrolled via an LAR, the subject must provide assent, the assent will be documented.\n3. LVEF ≤ 40%\n4. Subject is presenting with decompensated heart failure and meets at least one (1) of the following cardiogenic shock criteria:\n\n   1. Sustained episode of systolic blood pressure ≤ 90 mmHg for at least 30 minutes or need for vasoactive agents to maintain such blood pressure.\n   2. Cardiac index (CI) \\\u003C 2.2 L\u002Fmin\u002Fm2 determined to be secondary to cardiac dysfunction, in the absence of hypovolemia.\n   3. Require support with an intra-aortic balloon pump (IABP)\n   4. Serum lactate \\>2 mmol\u002FL\n5. Subject has inadequate heart failure GDMT based on the most recent outpatient prescription prior to index admission, defined as:\n\n   1. On 2 or less of the 4-Pillar HF Drug Classes (BB, MRA, SGLT2i, and RASi)\n   2. If on BB and RASi, at least one of the two medications is \\\u003C 50% of the maximal target dose.\n\nExclusion Criteria:\n\n1. Underlying unmodifiable conditions that limit initiation of GDMT prior to enrollment, including but not limited to:\n\n   1. Drug allergies or hypersensitivities\\* to HF GDMT medications, unless alternative can be identified.\n\n      \\*Drug allergy\u002Fhypersensitivity is an immune-mediated reaction to a medication. Adverse reactions must be a result of immune or inflammatory cell stimulations by the mеԁiсаtion.\n   2. Known bilateral renal artery stenosis\n   3. Type 1 diabetes\n   4. 2o or 3o AV block, unless pacemaker is in place\n   5. Angioedema, hereditary or idiopathic\n   6. Pregnancy, known or confirmed by a pregnancy test if of childbearing potential\n2. ST-segment elevation or acute coronary syndrome (ACS) prior to enrollment\n3. Septic shock, shock from non-cardiac origins, or mixed shock\n4. SCAI Stage E cardiogenic shock per study definition (Appendix C) prior to enrollment\n5. In cardiac arrest prior to enrollment\n6. Intra-aortic balloon pump (IABP) use \\>24 hours from the onset of cardiogenic shock if placed at the enrolling site or \\>48 hours if transferred on IABP prior to enrollment\n7. On mechanical circulatory support other than IABP (i.e. ECMO, Impella CP, etc) or on mechanical ventilation for non-procedural reasons prior to enrollment\n8. Revascularization or cardiac surgery within 30-days of the index hospitalization date or decision to undergo revascularization or cardiac surgery made prior to enrollment\n9. Infiltrative\u002Frestrictive cardiomyopathy (sarcoidosis and amyloidosis), hypertrophic cardiomyopathy, constrictive pericarditis, pericardiac tamponade, or fulminant myocarditis (giant cell or immune checkpoint inhibitor)\n10. Complex adult congenital heart disease\n11. Primary severe valvular disease\n12. Predominant RV dysfunction per Investigator's discretion\n13. History of heart transplant or listed for heart transplant or planned for heart transplantation prior to enrollment.\n14. Planned to be implanted with a permanent VAD within 180-days of the index hospitalization date.\n15. Continuous outpatient inotropic support prior to the index hospitalization date.\n16. Planned to pursue palliative care or hospice, or life expectancy of less than 1 year due to non-cardiac illness at the time of index hospitalization date.\n17. Currently on dialysis, or has pre-existing end-stage chronic kidney disease (stage 4 and above), or has nephropathy of hereditary, infectious, or autoimmune origin.\n18. Pre-existing liver disease including liver cirrhosis, alcoholic hepatitis, metabolic dysfunction associated steatohepatitis (MASH), or genetic liver disease.\n19. Pre-existing pulmonary disease with oxygen dependency.\n20. History of stroke or intracranial hemorrhage ≤ 90 days prior to the index hospitalization date, or a history of cerebrovascular disease with significant (\\> 80%) uncorrected carotid stenosis, or any permanent neurological deficit with modified Rankin Scale (mRS) \\>2.\n21. Any contraindication that precludes placing an Impella 5.5®, including but not limited to:\n\n    1. Aortic valve stenosis\u002Fcalcification with orifice area ≤ 0.6cm2 or aortic insufficiency of any grade greater than mild on pre-procedure echocardiography.\n    2. Presence of mechanical aortic valve or heart constrictive device\n    3. Thrombus in the left atrium or ventricle\n    4. Infection of the planned procedural access site or suspected systemic active infection.\n    5. Severe arterial disease precluding placement of Impella\n    6. Presence of Atrial or Ventricular Septal Defect\n    7. Left ventricular rupture\n    8. Cardiac tamponade\n    9. Combined cardiorespiratory failure\n22. Intolerance to anticoagulant or antiplatelet therapies, or will refuse blood transfusions.\n23. Subject has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent (or assent if LAR) and\u002For to comply with study procedures.\n24. Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device.\n25. Subject belongs to a vulnerable population, such as prisoners, pregnant women, handicapped, mentally disabled persons, or economically or educationally disadvantaged persons per 21CFR56.111(a)(3) and 111(b).",{"count":436,"type":22},250,[86],"The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.",[221,28,440],"Reduced Ejection Fraction Heart Failure",[197,442,440,136,443,444,445],"Heart Failure Cardiogenic Shock","Cardiovascular Disease","Heart Disease","Guideline Directed Medical Therapy","2026-04-20",{"date":448,"type":44},"2026-04-23",{"date":450,"type":22},"2026-04-01",{"date":452,"type":22},"2029-06-01",{"name":73,"class":74},7,{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":52},"100565137","transcatheter-aortic-valve-implantation-in-aortic-stenosis-cardiogenic-shock-100565137","NCT06638268","Transcatheter AortiC Valve Implantation in aorTic stenosIs CardiogenIc Shock","Transcatheter AortiC Valve Implantation in aorTic stenosIs CardiogenIc Shock - The TACTICS Study - A Randomized Controlled Trial","TACTICS","Inclusion Criteria:\n\n* Aortic valve area less than 1cm2\n\nAND\n\nCardiogenic Shock defined as:\n\n* Peripheral signs of tissue hypoperfusion (arterial blood lactate ≥2.5mmol\u002Fl) AND\n* Systolic blood pressure \\\u003C 100 mmHg and\u002For need for vasopressor therapy (dopamine\u002F norepinephrine or epinephrine) AND\n* Left ventricular ejection fraction ≤ 45%\n\nOR\n\n\\- Syncope\u002Fresuscitation (mechanical ventilation)\n\nExclusion Criteria:\n\n* Intracranial hemorrhage \\\u003C 1 month ago\n* Remaining life-expectancy \\\u003C 6 month due to other cause\n* Body mass index \\\u003C15 OR \\> 40\n* Clinical frailty score ≥6 before present worsening\n* Severe lung disease (forced expiratory volume in 1 second OR diffusion capacity of the lungs for carbon monoxide \\\u003C 25 of expected)\n* Unsuitable for TAVI prior to screening",{"count":217,"type":22},[86],"The goal of this clinical trial is to learn if acute transcatheter aortic valve implantation (TAVI) is superior to standard treatment (stabilization in an intensive care unit and TAVI subsequently) to treat cardiogenic shock in patients with critical severe aortic stenosis.\n\nThe main questions it aims to answer are:\n\n• Does acute TAVI increase survival compared with standard treatment?\n\nParticipants will:\n\n* Undergo either TAVI within 12 hours after admission or stabilization and TAVI 72 hours or more after admission\n* Visit an outpatient clinic and be evaluated for quality of life and heart function",[467,28],"Aortic Stenosis",[469,28,467,470,471,472,473,474,475],"Randomized Controlled Trial","Mortality","Frailty","Quality Of Life","Aortic Valve Stenosis","Transcatheter Aortic Valve Replacement","Transcatheter Aortic Valve Implantation","2026-04-17",{"date":478,"type":44},"2026-04-22",{"date":480,"type":44},"2024-11-25",{"date":482,"type":22},"2027-10-30",{"name":484,"class":51},"Rigshospitalet, Denmark",{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":497,"conditions":498,"keywords":502,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":52},"100633474","phase-4-prolonged-nasogastric-administration-of-ketones-in-decompensated-heart-failure-100633474","NCT07527156","Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure","Feasibility and Safety of Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure","KADHEF-2","Inclusion Criteria:\n\n* LVEF \\\u003C35%\n* Acute heart failure with low cardiac output syndrome or cardiogenic shock\n\nExclusion Criteria:\n\n* Severe liver failure\n* Severe acidosis\n* Inability to insert nasogastric tube\n* Gastric paralysis \u002F ileus\n* Repeated vomiting\n* Severe hypokalemia",{"count":494,"type":22},12,[496],"PHASE4","This study will evaluate the feasibility and safety of achieving therapeutic concentrations of beta-hydroxybutyrate using continuous infusion of D-beta-hydroxybutyrate monoester administered via a nasogastric tube in patients with acutely decompensated heart failure with reduced left ventricular ejection fraction.",[499,28,221,500,501],"Acute Heart Failure (AHF)","Ketones","Ketone Body Metabolism",[503,504,505],"acute heart failure","ketones","ketone body","2026-04-07",{"date":508,"type":44},"2026-04-14",{"date":510,"type":44},"2026-04-04",{"date":512,"type":22},"2027-03-31",{"name":514,"class":515},"Institute for Clinical and Experimental Medicine","OTHER_GOV",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":23,"phases":526,"briefSummary":527,"conditions":528,"keywords":529,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":543},"100619510","personalisation-of-mean-arterial-pressure-in-adult-patients-with-cardiogenic-shock-100619510","NCT07345559","Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock","Prospective, Randomized, Multicenter, Controlled Trial Assessing the Personalization of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock","CARDIOPAM","Inclusion Criteria:\n\n* Aged ≥18 years\n* Cardiogenic shock state, according to the consensus definition,\n* SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C\n* Consent from the patient or close relative \u002F trusted person or emergency inclusion procedure\n* Benefiting fromciary of a social security scheme\n\nExclusion Criteria:\n\n* Catecholamine infusion for more than 24 consecutive hours;\n* CVP \\\u003C 5 mm Hg at inclusion;\n* MAP \\> 70 mmHg at inclusion;\n* Chronic kidney disease stage G4 (defined by an eGFR between 15-29 ml\u002Fmin\u002F1.73 m²) or G5 (defined by an eGFR less than 15 ml\u002Fmin\u002F1.73 m²) according to the KDIGO CKD classification at inclusion;\n* Chronic dialysis or presence of renal replacement therapy criteria at inclusion ;\n* Recovered cardiopulmonary arrest within 7 days prior to inclusion;\n* Patient already on mechanical circulatory support at inclusion before enrollment (patients who receive support after inclusion will not be excluded);\n* Primary diagnosis of tamponade, pulmonary embolism, or septic shock;\n* Hypersensitivity to norepinephrine tartrate or to any of the following excipients: sodium chloride, hydrochloric acid or sodium hydroxide water for injectable preparations;\n* Absence of central venous access;\n* Known pregnancy or current breastfeeding;\n* Under legal guardianship, curatorship, or judicial protection.",{"count":525,"type":22},406,[86],"Cardiogenic shock is a life-threatening condition characterized by inadequate cardiac output, leading to organ hypoperfusion and high mortality. Maintaining mean arterial pressure (MAP) is crucial, but standard targets may be insufficient due to venous congestion. Central venous pressure (CVP) can help assess effective perfusion pressure. This study investigates whether a personalized MAP target adjusted by CVP improves organ function and survival compared to standard MAP management.",[28],[98,530,531,532,533,534,470],"Inotropes","vasopressors","Mean arterial pressure","Central Venous Pressure","Organ dysfunction",{"date":536,"type":44},"2026-04-02",{"date":538,"type":44},"2026-03-26",{"date":540,"type":22},"2029-07-25",{"name":542,"class":51},"CMC Ambroise Paré",11,{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":75},"100632578","multimodal-phenotyping-in-patients-referred-with-acute-cardiac-failure-100632578","NCT07515508","Multimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE","MIRACLE","Inclusion Criteria:\n\n* Patients hospitalized with acute heart failure SCAI stage B - E.\n\nExclusion Criteria:\n\n* Not capable of providing informed consent due to reasons not attributable to cardiogenic shock\n* Cardiogenic shock following cardiothoracic surgery",{"count":263,"type":22},"The goal of this observational study is to learn whether information collected during routine hospital care, together with blood and urine samples, can help doctors better identify different types of cardiogenic shock and better predict outcomes in adults hospitalized with acute heart failure and cardiogenic shock. The main question is whether clinical findings, imaging results, and biomarkers, including sex-specific factors, are associated with the risk of death within 30 days. Participants will not receive an experimental treatment. Researchers will collect data from routine care, collect additional blood and urine samples for biobanking, and follow participants after hospital discharge",[28,499],"2026-03-31",{"date":506,"type":44},{"date":557,"type":44},"2024-08-07",{"date":559,"type":22},"2028-07-31",{"name":561,"class":51},"University Heart Center Freiburg - Bad Krozingen",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":569,"targetDuration":571,"studyType":63,"phases":4,"briefSummary":572,"conditions":573,"keywords":576,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":52},"100632069","characterisation-of-phenotypes-in-acute-heart-failure-patients-100632069","NCT07508891","Characterisation of phenotYpes in aCute Heart faiLure patiEnts","CYCLE","Inclusion Criteria:\n\n* Clinical diagnosis of acute heart failure, including all stages of cardiogenic shock, de novo heart failure as well as decompensated chronic heart failure.\n* Hospitalisation due to acute heart failure or new-onset acute heart failure during a hospitalisation de to a different cause. Out-patients with acute heart failure are not included.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* No written informed consent.",{"count":570,"type":22},1000,"10 Years","An observational cohort study to evaluate the benefit of functional parameters, radiomics and blood biomarkers to predict the outcome of patients with acute heart failure.",[574,575,28],"Acute Heart Failure","Decompensated Heart Failure",[168,503,577,578,579,580,581,582],"heart failure","biomarker","biobank","cohort study","phenotyping","risk prediction","2026-03-30",{"date":536,"type":44},{"date":586,"type":44},"2019-03-01",{"date":588,"type":22},"2030-12-31",{"name":590,"class":51},"Universitätsklinikum Hamburg-Eppendorf",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":603,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":52},"100452204","phase-4-clinical-outcome-and-cost-effectiveness-of-reduced-noradrenaline-by-using-a-lower-blood-pressure-target-in-patients-with-cardiogenic-shock-from-acute-myocardial-infarction-100452204","NCT05168462","Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction","NORSHOCK","Inclusion criteria:\n\n1. Acute myocardial infarction, STEMI or NSTEMI\n2. Early revascularization by PCI\n3. Cardiogenic shock, characterized by:\n\nI. a. Systolic blood pressure (SBP) ≤ 90 mmHg for \\> 30 minutes, OR b. Use of drugs to maintain SBP \\> 90 mmHg at randomization.\n\nII. Clinical signs of impaired organ perfusion with at least one of the following criteria:\n\n1. Altered mental status\n2. Cold, clammy skin and extremities\n3. Oliguria with urine output \\\u003C 30ml\u002Fhour\n4. Serum lactate \\> 2.0 mmol\u002FL\n\nIII. Clinical signs of pulmonary congestion\n\nExclusion Criteria:\n\n1. Resuscitation \\> 30 minutes\n2. Mechanical cause of cardiogenic shock (e.g. papillary muscle rupture, ventricular septal rupture)\n3. Onset of shock \\> 12 hours\n4. Imminent need for mechanical circulatory support (i.e. ECPR)\n5. Women \\\u003C45 years",{"count":599,"type":22},776,[496],"Rationale: Pump failure due to acute myocardial infarction (AMI) can lead to cardiogenic shock (CS): a state of low blood flow to end-organs with subsequent multi-organ failure that is associated with high mortality rated. The first line pharmacologic treatment strategy in CS is noradrenaline. This vasopressor drug is used to maintain adequate blood pressures. The assumption is that a mean arterial blood pressure (MAP) ≥ 65 mmHg will improve flow and thereby tissue perfusion of myocardium and other tissues (e.g. renal). However, there is no evidence that an increase in MAP, if achieved by noradrenaline, leads to greater end-organ blood flow and better outcomes.\n\nObjective: With this study the investigators aim to investigate the (cost-)effectiveness of reduced noradrenaline in patients with CS by using a lower MAP target of ≥ 55 mmHg, compared to ≥ 65 mmHg. The investigators hypothesize that reduced use of noradrenaline will improve overall survival and decrease renal failure requiring renal replacement therapy.\n\nStudy design: Open label, randomized controlled multicenter trial\n\nStudy population: Adults patients with CS due to AMI\n\nIntervention: Treatment strategy of reduced noradrenaline, by using a lower MAP target ( ≥ 55 mmHg).\n\nMain study endpoint: composite of all-cause mortality and severe renal failure leading to renal replacement therapy within 30-days after randomization.",[28,138],[604,605,98,606],"Noradrenaline","Blood pressure target","Myocardial infarction","2026-03-24",{"date":609,"type":44},"2026-03-27",{"date":611,"type":44},"2022-10-01",{"date":613,"type":22},"2028-04-01",{"name":615,"class":51},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":624,"conditions":625,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":632,"leadSponsor":634,"locationsCount":52},"100630219","evaluation-of-acid-base-disorders-and-ventilation-settings-in-cardiogenic-shock-and-post-cardiac-arrest-patients-comparison-with-ventilo-algorithm-100630219","NCT07484828","Evaluation of Acid-base Disorders and Ventilation Settings in Cardiogenic Shock and Post-cardiac Arrest Patients: Comparison With VentilO Algorithm","VentilO CU","Inclusion Criteria:\n\n* Adult (Age \\>=18 years old)\n* Under mechanical ventilation with endotracheal tube for :\n\npost cardiac arrest or cardiogenic shock\n\n\\- Bood gases result availability up to 4 hours after coronary unit admission\n\nExclusion Criteria:\n\n* Lack of patient anthropometric data (height and weight) available in the patient record\n* No information in the record regarding the data on the humidification systems used at the time of the first blood gas test upon admission to the coronary care unit.\n* Patient stabilzed in other hospital before coronary unit admission or adjustment of respiratory parameters after a blood gas test.",{"count":192,"type":22},"This study aims to better understand how mechanical ventilation settings affect patients admitted to the coronary care unit after cardiac arrest or with cardiogenic shock. These patients often require mechanical ventilation, but current guidelines provide limited evidence on the best approach. Improper ventilation settings can lead to acid-base imbalances, such as respiratory acidosis or alkalosis, which may worsen patient outcomes.\n\nThe retrospective analysis will include 100 adult patients (50 post-cardiac arrest and 50 with cardiogenic shock) who were mechanically ventilated upon admission. The study has two main objectives:\n\nDetermine how often acid-base disorders occur in these patients and describe their characteristics.\n\nCompare the initial ventilator settings chosen by clinicians with those suggested by VentilO, a decision-support algorithm.\n\nThe investigators will evaluate the potential effect of the VentilO recommendations on the first arterial (or capillary) blood gases compared to the real settings.\n\nThis information will help refine the algorithm and guide future research on improving ventilation strategies for critically ill cardiac patients.\n\nParticipation does not involve any intervention, as the study uses existing medical records.",[626,28,93,627],"Cardiac Arrest (CA)","Acid Base Disorder","2026-03-18",{"date":630,"type":44},"2026-03-20",{"date":226,"type":22},{"date":633,"type":22},"2026-12",{"name":635,"class":51},"Laval University",{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":18,"minAge":385,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":23,"phases":645,"briefSummary":646,"conditions":647,"keywords":652,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":656,"startDateStruct":657,"completionDateStruct":658,"leadSponsor":660,"locationsCount":662},"100630068","routine-versus-provisional-distal-perfusion-catheter-placement-in-patients-undergoing-mechanical-circulatory-support-100630068","NCT07482865","Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support","PERFUSE-MCS","Inclusion Criteria:\n\n* Patients aged 19 years old\n* Cardiogenic shock requiring mechanical circulatory support through femoral artery approach\n* Subject who can verbally confirm understandings of risks and benefits of receiving distal perfusion catheter insertion and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n* Under the critically-ill clinical circumstance (unclear consciousness of patient), legally authorized representative can provide written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Apparent symptoms and sign of acute limb ischemia immediately after mechanical circulatory support insertion\n* Significant coagulopathy precluding invasive procedure due to high risk of bleeding\n* Pregnant women, women with potential childbearing, or lactating women\n* Irreversible limb ischemia requiring interventional procedures or surgery at the time of MCS insertion\n* Previous history if femoral-femoral bypass grafting or femoral-popliteal bypass grafting\n* Previous history of limb amputation\n* Unwilling or unable to obtain informed consent from the participant or legally authorized representative",{"count":644,"type":22},500,[86],"A prospective, multi-center, open label, randomized controlled, superiority trial to compare clinical outcomes between routine distal perfusion catheter (DPC) insertion versus provisional distal perfusion catheter (DPC) insertion in the occurrence of sign or symptom of acute limb ischemia in patients undergoing mechanical circulatory support (MCS) through femoral artery approach.",[28,648,649,650,651],"Acute Myocardial Infarction of Inferior Wall","Congestive Heart Failure","Myocarditis","Acute Limb Ischemia",[28,653,654,649,655],"Distal perfusion catherter","Acute Myocardial Infarction","Limb ischemia",{"date":630,"type":44},{"date":398,"type":22},{"date":659,"type":22},"2030-10-31",{"name":661,"class":51},"Samsung Medical Center",6,{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":667,"acronym":668,"eligibilityCriteria":669,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":670,"targetDuration":671,"studyType":63,"phases":4,"briefSummary":672,"conditions":673,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":674,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":678,"locationsCount":680},"100453511","multi-center-collaborative-to-enhance-quality-and-outcomes-in-the-management-of-cardiogenic-shock-100453511","NCT05185492","Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock","VANQUISH SHOCK","Inclusion Criteria:\n\n* Primary diagnosis of cardiogenic shock at time of index evaluation; including acute myocardial infarction- and acute decompensated heart failure-cardiogenic shock phenotypes\n* Patients with cardiac arrest complicating cardiogenic shock and those with massive pulmonary embolism with right ventricular cardiogenic shock will also be eligible for the registry\n\nExclusion Criteria:\n\n* Patients with shock not due to primary cardiac etiology will be excluded. These include septic, hemorrhagic, and anaphylactic shock.",{"count":644,"type":22},"1 Year","This large real-world international prospective registry will provide a unique opportunity to comprehensively understand the contemporary management, clinical course and short as well as long-term outcomes of all Cardiogenic Shock (CS) patients cared for at four high volume dedicated shock care centers. As the first true North American multicenter CS collaborative with a uniform dedicated and comprehensive case report form, the high patient volumes and wide spectrum of clinical acuity seen at these institutions will provide valuable insight into the factors associated with adverse outcomes; and will serve as a blueprint for future clinical trial designs that may better inform clinical practice.",[28,654],{"date":630,"type":44},{"date":676,"type":44},"2022-05-25",{"date":71,"type":22},{"name":679,"class":51},"STAVROS G DRAKOS",3]